Get the Stockscreener App
26.66
0.23%
0.06
After Hours:
26.66
Royalty Pharma Plc stock is traded at $26.66, with a volume of 1.33M.
It is up +0.23% in the last 24 hours and down -1.80% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$26.60
Open:
$26.6
24h Volume:
1.33M
Relative Volume:
0.59
Market Cap:
$11.85B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
236.98
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
+0.87%
1M Performance:
-1.80%
6M Performance:
+1.02%
1Y Performance:
-0.89%
1-Day Range:
$26.46
$26.66
1-Week Range:
$26.02
$26.83
52-Week Range:
$25.10
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
26.66 | 11.85B | 2.24B | 673.24M | 2.67B | 1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Eventide Asset Management LLC Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Charles Schwab Investment Management Inc. Has $84.92 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Citigroup Inc. Has $14.95 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times
Royalty Pharma to Present at Two Major Healthcare Investor Conferences in December | RPRX Stock News - StockTitan
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? - MSN
Dai ichi Life Insurance Company Ltd Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Qsemble Capital Management LP Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
10 Cheapest Stocks to Buy On Robinhood - Insider Monkey
(RPRX) Trading Advice - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Thrivent Financial for Lutherans Purchases 168,905 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Overbrook Management Corp Sells 59,504 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Victory Capital Management Inc. - MarketBeat
RPRXRoyalty Pharma plc Latest Stock News & Market Updates - StockTitan
Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Plc: Revolutionizing Biopharma with Synthetic Royalty Funding Innovations!Major Drivers - Smartkarma
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Simplify Asset Management Inc. - MarketBeat
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool
Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St
Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Baillie Gifford & Co. - MarketBeat
Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q3 2024 Earnings Preview - MSN
Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat
Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha
Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com
Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance
Royalty Pharma Reports Strong Q3 2024 Results - TipRanks
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria
Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):